

# KYOWA KIRIN

## News Release

### **Kyowa Hakko Kirin California Announces Appointment of Andrew McKnight, Ph.D. as Chief Scientific Officer**

**La Jolla, CA, May 18, 2015** -- Kyowa Hakko Kirin California, Inc. (President: Yasunori Yamaguchi, Ph.D.; headquartered in La Jolla, California, "KKC"), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151; President and CEO: Nobuo Hanai, Ph.D.), announced today the appointment of Andrew McKnight, Ph.D. as Chief Scientific Officer (CSO), effective May 18, 2015. Dr. McKnight brings to KKC extensive experience in the design and development of novel therapeutics in the therapeutic areas of Inflammation, Autoimmunity, and Allergy. In his new role as CSO, Dr. McKnight will be heading KKC's Research Division.

"We are pleased to bring Andrew's experience to KKC to drive the advancement of our drug discovery portfolio, as well as the initiation of new pipeline projects," said Yasunori Yamaguchi, Ph.D., President of KKC. "Dr. McKnight is extremely well qualified to serve as CSO. His extensive leadership experience will be a strong complement to our executive team and will be invaluable as we continue to establish a competitive drug discovery organization."

Most recently, Dr. McKnight served as Vice President of Target and Translational Biology at AnaptysBio where he successfully introduced multiple antibody programs, including those targeting interleukin-33 (IL-33) and interleukin-36 receptor (IL-36R).

Dr. McKnight brings additional leadership experience from companies including UCB-Celltech, and Pfizer's Biotherapeutics R&D organization in Cambridge, MA.

Dr. McKnight earned his doctorate from University of Oxford and was a postdoctoral fellow at Harvard Medical School.

#### **Contact:**

Kyowa Hakko Kirin California, Inc.  
9420 Athena Circle  
La Jolla, CA 92037  
858-952-7000  
info@kyowa-kirin-ca.com  
<http://kyowa-kirin.com/kkc>